This article is more than 5 years old. Information may no longer be current.

Allergan exercises third option for Molecule Partners’ DARPin products

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan has exercised a third option to develop and commercialize DARPin product candidates from Molecular Partners and will receive an exclusive license for select multi-DARPin candidates in ophthalmology, according to a Molecular Partners press release.

DARPin products, a class of protein therapeutics, include the long-acting mono-DARPin abicipar, a drug candidate that inhibits VEGF-A and is currently under investigation for the treatment of wet age-related macular degeneration and diabetic macular edema.

For the exercise of the third option, Allergan will pay regulatory and sales milestone payments up to $320 million to Molecular Partners, as well as tiered royalty payments on future product sales, the release said.